Presented by:
Mary Carrington, Ph.D.
Laboratory of Experimental Immunology, Senior Investigator, Center for Cancer Research
National Cancer Institute

The main goal of Dr. Carrington's laboratory is to understand the genetic basis for resistance or susceptibility to disease conferred by HLA and KIR loci. Her approach involves direct testing for genetic effects of polymorphic genes within the MHC, as well as functionally relevant combinations of HLA class I alleles and KIR genes, on specific disease outcomes.

Light lunch served

Co-Sponsored by the Jonsson Comprehensive Cancer Center, The Department of Pathology & Laboratory Medicine and the UCLA AIDS Institute